welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Earlier start of corticosteroids in DMD linked to earlier heart disease onset, study suggests
Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease outcomes.
The study, “Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy,” was published in the journal Neuromuscular Disorders.
DMD is an inherited childhood-onset disease characterized by mutations in the DMD gene that provides instructions for making a protein called dystrophin, located primarily in skeletal muscles used for movement and in the heart muscle. These mutations lead to progressive muscle weakness.
rareRelated
-
Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Gluco...OBJECTIVE: To evaluate clinical outcome...
-
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophyObjective: To assess safety and efficac...
-
Longitudinal Pulmonary Function Testing Outcome Measures in Duchenne Muscular Dystrophy: Long-term Natural History w...We describe changes in pulmonary functio...
-
Developing standardized corticosteroid treatment for Duchenne muscular dystrophyDespite corticosteroids being the only t...
-
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortThis is an open label, long-term extensi...
-
CoQ10 and Prednisone in Non-Ambulatory DMDThis study will help determine if CoQ10 ...
-
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of DeflazacortPTC Therapeutics, Inc. today announced t...